pharma · No medical condition. · Generalized Myasthenia Gravis
Anaxis Pharma
Lacuna Pharma Pty Ltd
Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2017
- Employees
- 7
- Programs
- 642
- Drugs
- 673
- Patents
- 0
ASND0029
Phase 2 · small molecule · Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer
ASND0029 for Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code ASND0029
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lacuna Pharma Pty Ltd
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer
- Status
- active
- Trials
- 1